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Abstract
Fibroblast growth factors (FGFs) mediate a vast range of CNS developmental processes including neural induction,
proliferation, migration, and cell survival. Despite the critical role of FGF signaling for normal CNS development, few reports
describe the mechanisms that regulate FGF receptor gene expression in the brain. We tested whether FGF8 could
autoregulate two of its cognate receptors, Fgfr1 and Fgfr3, in three murine cell lines with different lineages: fibroblast-derived
cells (3T3 cells), neuronal cells derived from hippocampus (HT-22 cells), and neuroendocrine cells derived from hypothalamic
gonadotropin-releasing hormone (GnRH) neurons (GT1-7 cells). GnRH is produced by neurons in the hypothalamus and is
absolutely required for reproductive competence in vertebrate animals. Several lines of evidence strongly suggest that Fgf8 is
critical for normal development of the GnRH system, therefore, the GT1-7 cells provided us with an additional endpoint, Gnrh
gene expression and promoter activity, to assess potential downstream consequences of FGF8-induced modulation of FGF
receptor levels. Results from this study suggest that the autoregulation of its cognate receptor represents a common
downstream effect of FGF8. Further, we show that Fgfr1 and Fgfr3 are differentially regulated within the same cell type,
implicating these two receptors in different biological roles. Moreover, Fgfr1 and Fgfr3 are differentially regulated among
different cell types, suggesting such autoregulation occurs in a cell type-specific fashion. Lastly, we demonstrate that FGF8b
decreases Gnrh promoter activity and gene expression,possibly reflecting a downstreamconsequence of altered FGF receptor
populations. Together, our data bring forth the possibility that, in addition to the FGF synexpression group, autoregulation of
FGFR expression by FGF8 represents a mechanism by which FGF8 could fine-tune its regulatory actions.
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Introduction
Fibroblast growth factors (FGFs) mediate a vast range of CNS
developmental processes including neural induction, proliferation,
migration, and cell survival. The FGF family consists of four
receptors (FGFR1, 2, 3, 4), 22 ligands, and their splice variants that
vary in expression patterns both temporally and spatially [1]. The
structural components of FGF receptors consist of three extracellular
Ig-like domains, a transmembrane domain, and two intracellular
tyrosinekinasedomains[2].DespitethecriticalroleofFGFsignaling
in CNS development, there are few reports to date describing the
mechanismsthatregulateFGFreceptorgeneexpressioninthebrain.
Receptor expression is often controlled by autoregulation,
where binding of the cognate ligand leads to changes that affect
protein turnover, internalization, primary transcript stability, and
gene promoter activity [3,4,5]. Interestingly, FGFR1 was reported
to have a synexpression pattern with its cognate ligand FGF8 [6].
Synexpression is an interesting feature associated with FGF and a
few other signaling pathways that involves the coexpression of a set
of genes termed the synexpression group [7,8,9]. The products of
the FGF synexpression group are then capable of modulating the
intracellular signaling cascades of several FGF ligands, in
particular FGF8, to curtail or achieve specific spatial patterns of
FGF signaling [10]. This raises the possibility that FGF8 may
control its own activity level via the autoregulation of its own
receptors. The upregulation of FGFR1 by FGF8 could represent a
positive feedback mechanism that adds another layer of regulatory
complexity, further fine-tuning the spatial and temporal specificity
of FGF8 actions during development.
Until now, the possibility that FGF8 could add to the modular
regulation of its activity in neurons by autoregulating its own
receptor has not been adequately explored. Further, it is unclear if
FGF8 could autoregulate all cognate receptors in a similar fashion.
In this study, we examined if FGF8 autoregulated two of its
cognate receptors, Fgfr1 and Fgfr3, in three murine cell lines with
different lineages: fibroblast-derived cells (3T3), neuronal cells
derived from hippocampus (HT-22), and neuroendocrine cells
derived from hypothalamic gonadotropin-releasing hormone
neurons (GT1-7). The GT1-7 cells were particularly useful since
the in vivo specification of GnRH neuronal fate was shown to be
highly dependent on FGF8 signaling and, the expression level of
FGF receptors in these cells could be correlated with a hallmark of
GnRH neuronal differentiation: the expression of Gnrh gene [11].
Therefore, these cells provided us with an additional endpoint,
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10143Gnrh gene expression and promoter activity, to assess potential
downstream consequences of FGF8-induced modulation of FGF
receptor levels.
Results
Endogenous expression of FGF8 in 3T3, HT-22, and GT1-7
cell lines
First, we characterized the endogenous expression of FGF8 in
the 3T3, HT-22, and GT1-7 and compared it with mouse tissue
taken from embryonic nasal explants and adult hypothalamus.
Consistent with the widely accepted role of FGF8 during
development, mouse nasal explants had high expression levels of
endogenous FGF8 (Fig. 1, lane 2). Also, 3T3 cells had high
endogenous levels of FGF8 (Fig. 1, lane 6) which was expected due
to their fibroblast cell lineage. By contrast, endogenous FGF8
expression was low in the neuronal-derived HT-22 cells (Fig. 1,
lane 5) and completely absent in the GT1-7 cells and
hypothalamus (Fig. 1, lanes 3 and 4, respectively).
Differential effects of FGF8b on the expression of FGF
receptors 1 (Fgfr1) and 3 (Fgfr3)
In these experiments, 3T3, HT-22, and GT1-7 cells were
treated with 5 or 50 ng/ml of FGF8b for 4 hours in order to
determine if FGF8b regulated the expression of its cognate
receptors Fgfr1 and Fgfr3 in these cell types. Overall, our data
revealed that FGF8b differentially altered the expression of Fgfr1
and Fgfr3 mRNA depending on the cell type. For instance, in 3T3
cells, which express high endogenous levels of FGF8, FGF8b
treatment for 4 hours significantly increased Fgfr1 mRNA (Fig. 2A),
yet had no effect on Fgfr3 (Fig. 2B). By contrast, in HT-22 cells,
which express low endogenous levels of FGF8, FGF8b treatment
had no effect on Fgfr1 (Fig. 2C), yet significantly decreased Fgfr3
mRNA (Fig. 2D). Most notably, in the GT1-7 cells, which do not
express endogenous FGF8, FGF8b treatment significantly in-
creased Fgfr1 expression (Fig. 2E) while simultaneously decreasing
Fgfr3 expression (Fig. 2F). This differential effect of FGF8b on
Fgfr1 and Fgfr3 receptor expression in GT1-7 cells did not occur in
the HT-22 or 3T3 cells. Therefore, in a subsequent experiment,
GT1-7 cells were used to determine whether the differential effects
of FGF8b on Fgfr1 and Fgfr3 expression are mediated through the
classical membrane FGF receptors.
FGF8b effects on FGF receptor expression in GT1-7 cells
are mediated by FGF receptors
In these experiments, GT1-7 cells were treated with FGF8b
(50 ng/ml), the FGF receptor antagonist PD173074 (100 nM), or
combined FGF8b + PD173074 for 8 hours. Consistent with our
earlier observation, treatment with FGF8b alone significantly
increased Fgfr1 (Fig. 3A). Moreover, the FGF receptor anatagonist
PD173074, alone or in combination with FGF8b, significantly
inhibited Fgfr1 mRNA expression compared to the vehicle group
(Fig. 3A). Also consistent with our earlier observation in GT1-7
cells, FGF8b treatment significantly decreased Fgfr3 mRNA
(Fig. 3B), but there was no effect of PD173074 alone on the
expression of Fgfr3. The inhibitory effect of FGF8b on Fgfr3 was
completely abolished in the presence of the antagonist (Fig. 3B).
FGF8b decreased gonadotropin-releasing hormone
promoter activity and mRNA in GT1-7 cells
Previous work demonstrated that targeted disruption of Fgfr1
signaling in GnRH neurons decreased the numbers of detectable
GnRH neurons in the hypothalamus of adult mouse brain,
suggesting that FGF is critical for normal GnRH neuronal
development [12] Based on this observation, we hypothesized
that that the expression level of the Gnrh gene, a hallmark of
GnRH neuronal differentiation, could vary according to Fgfr1, and
possibly Fgfr3, levels [11]. Further, in the previous experiment we
determined that FGF8b differentially altered the expression of its
two cognate receptors, Fgfr1 and Fgfr3 in a GnRH-expressing cell
line (GT1-7 cells; see Fig. 2E, F). Therefore, we measured Gnrh
promoter activity and mRNA levels in GT1-7 cells following
treatment with FGF8b to determine whether changes in the FGF
receptor population (i.e increased Fgfr1 and decreased Fgfr3)
corresponded to changes in Gnrh gene activity.
GT1-7 cells were treated with 5 or 50 ng/ml of FGF8b for 4 or
8 hours. Treatment with either 5 or 50 ng/ml of FGF8b
significantly reduced Gnrh mRNA in GT1-7 cells after 8, but not
4 (data not shown), hours of FGF8b exposure (Fig. 4A). To
determine whether the effects of FGF8b on Gnrh expression in
Figure 1. FGF expression in mouse brain and representative
cell lines. Photomicrograph of RT-PCR product for FGF8 mRNA stained
with ethidium bromide and resolved on a 2% agarose gel. Total RNA
was isolated from mouse nasal explant (embryonic day 11.5; lane 2)
adult hypothalamus (lane 3), hypothalamic-derived GT1-7 cells (lane 4),
hippocampus-derived HT-22 cells (lane 5), and fibroblast-derived 3T3
cells (lane 6). Presence of band indicates FGF8 primary transcripts in
representative tissue type or cell line.
doi:10.1371/journal.pone.0010143.g001
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were treated with the broad FGF receptor antagonist PD173074.
As expected, FGF8b treatment concomitant with the receptor
antagonist had no effect on Gnrh mRNA levels (Fig. 4B), indicating
that the FGF8b-induced decrease in Gnrh mRNA in GT1-7 cells
was dependent upon its cognate membrane receptors. Interest-
ingly, treatment with PD173074 alone induced a modest, yet
significant, decrease in Gnrh mRNA levels, similar that observed
previously with Fgfr1 (compare to Fig. 3A). Next, we measured
Gnrh promoter activity following FGF8b treatment in GT1-7 cells.
Treatment with FGF8b for 8 hours significantly reduced Gnrh
promoter activity in GT1-7 cells (Fig. 5) in parallel to the observed
reduction in Gnrh mRNA levels (compare to Fig. 4A). Further, the
concomitant treatment with PD17074 abolished the FGF8b-
induced reduction in promoter activity in GT1-7 cells.
Discussion
Precisely timed and coordinated FGF signaling events are
critical for proper CNS development, yet the mechanisms
regulating the expression of specific membrane FGF receptors in
neurons have not been thoroughly investigated. From our data,
the following general conclusions can be drawn. First, FGF8b
autoregulates the gene expression of its two cognate receptors,
Fgfr1 and Fgfr3, in a cell-type specific manner; second, this
autoregulation is mediated by FGF receptors as opposed to a non-
classical signaling pathway; third, receptor specific autoregulation
might be dependent upon the levels of endogenous FGF8 present
in a given cell type; and finally, FGF8b decreases Gnrh promoter
activity and gene expression, possibly reflecting a downstream
consequence of altered FGF receptor populations.
Ligand-mediated receptor autoregulation is a common feature
of many types of receptors, but there are few reports documenting
this as a mechanism for regulating FGF receptor gene expression.
FGF receptors belong to a large class of cell surface receptors
called receptor tyrosine kinases (RTKs) which encompasses
multiple receptor families, including the epidermal growth factor
(EGF), vascular endothelial growth factor (VEGF), RET, and Eph
receptor families [1,2,13]. The initial reports characterizing the
discovery of an FGF receptor noted that basic FGF (FGF2)
downregulated the number of available FGF binding sites in baby
hamster kidney cells [14]. These results were later confirmed in the
fibroblast-derived 3T3 cell line [15] and in pancreatic-derived
AR4-2J cells [16]. Interestingly, while FGF2 downregulated Fgfr1
Figure 2. Comparative effects of FGF8b on Fgfr1 and Fgfr3 mRNA in 3T3, HT-22 and GT1-7 cells. Fgfr1 and Fgfr3 mRNA levels in 3T3 cells
(A, B), HT-22 cells (C, D), or GT1-7 cells (E,F) following treatment with vehicle or FGF8b at 5 or 50 ng/ml. for 4 hours. Data are expressed as mean
copies of Fgfr1 or Fgfr3 transcript/mg total RNA 6 SEM. Dissimilar letters indicate statistically significant difference among groups, P,0.05.
doi:10.1371/journal.pone.0010143.g002
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upregulated Fgfr1 levels in those same cells by increasing the half-
life of the Fgfr1 transcript [16]. For our studies, FGF8b, was chosen
over other FGF8 isoforms based on the greater requirement of
FGF8b during CNS development [17,18]. In this respect, the
earlier findings are consistent with our current data in supporting
the autoregulatory effects of an FGF ligand on its own receptors, at
the level of transcription.
The four FGF receptors and their associated splice variants
share a considerable amount of overlap in their tissue distribution,
ability to bind multiple FGF ligands, and their intracellular
signaling pathways. Despite this redundancy, there is mounting
evidence that each receptor confers distinct downstream cellular
functions. Studies using the tumorigenic pro-B cell line, BaF3,
showed that a majority of the FGF ligands are more effective at
inducing mitogenic activity through Fgfr1 than the other FGF
receptor types [1]. Moreover, abnormally high levels of Fgfr1 gene
expression have been observed in prostate, colorectal, bladder,
and a subset of breast carcinomas [13,19,20,21]. Together, these
studies suggest that Fgfr1 is important for maintaining or inducing
Figure 3. Differential effects of FGF8b on Fgfr1 and Fgfr3 mRNA in GT1-7 cells. Fgfr1 (A) and Fgfr3 (B) mRNA levels in GT1-7 cells following
treatment with vehicle, FGF8b (50 ng/ml), PD173074 (100 nM), or FGF8b + PD173074 for 8 hours. Data are expressed as mean copies of Fgfr1 or
Fgfr3/mg total RNA 6 SEM. Dissimilar letters indicate statistically significant difference among groups, P,0.05.
doi:10.1371/journal.pone.0010143.g003
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shown that Fgfr3 can inhibit cellular proliferation in multiple cell
types including bone, pancreas, and brain [22,23,24,25]. Further,
a reciprocal relationship between Fgfr1 and Fgfr3 was observed in
colorectal carcinoma cells [20]. In that study, the transcriptional
silencing of Fgfr1 with siRNA decreased cellular proliferation and
increased Fgfr3 expression, suggesting that Fgfr3 was important for
limiting the progression of tumorigenesis. The only cell line in the
present study that recapitulated the reciprocal relationship
between Fgfr1 and Fgfr3 was GT1-7 cells (Fig. 2). As such, we
hypothesize that Fgfr1 and Fgfr3 both mediate biologically
important, but opposing, effects in these cells. FGF8 could favor
effects mediated by Fgfr1 by upregulating Fgfr1 and downregulat-
ing the antagonizing Fgfr3. These data put forth a novel
mechanism by which a ligand with multiple receptors could
preferentially activate pathways associated with one receptor
subtype. This regulatory mechanism would offer both flexibility
and selectivity during development, when multiple ligands and
their receptors are present at the same time.
Strong evidence suggests that FGF8 signaling, through its
cognate receptor Fgfr1, is critical for normal development of the
GnRH system. Mice hypomorphic for Fgf8 or Fgfr1 possessed
Figure 4. FGF8b decreased GnRH mRNA in GT1-7 cells. Panel A: GnRH mRNA levels in GT1-7 cells following 8 hours of vehicle or FGF8b
treatment at 5 or 50 ng/ml. Panel B: GnRH mRNA levels in GT1-7 cells following treatment with vehicle, FGF8b (50 ng/ml), PD173074 (100 nM), or
FGF8b + PD173074 for 8 hours. Data are expressed as mean copies of GnRH transcript/mg total RNA 6 SEM. Dissimilar letters indicate statistically
significant difference among groups, P,0.05.
doi:10.1371/journal.pone.0010143.g004
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Fgfr3-null mice showed no developmental deficiencies in GnRH
neurons (13). In this respect, Fgfr1 and Fgfr3 are clearly not
functionally equivalent in driving GnRH neuronal system
development, although both are expressed in GnRH neurons
[26]. In GT1-7 cells treated with FGF8b, an increase in Fgfr1/
Fgfr3 ratio was accompanied by a concomitant decrease in Gnrh
mRNA. Extrapolating these results to the endogenous GnRH
neurons, FGF8b could induce a general suppression of Gnrh gene
expression during early development via the preferential activation
of Fgfr1, a phenomenon consistent with low levels of Gnrh gene
expression in GnRH neurons before birth [27]. However, the
physiological significance of this finding in the endogenous GnRH
system requires further exploration.
Overall, our data demonstrate that autoregulation of FGFRs is
a cell-type specific process that leads to altered downstream
consequences due to individual receptor signaling events. At
present, the molecular mechanisms regulating FGF ligand-induced
receptor autoregulation and the resulting downstream effects are
unclear. However, the data herein provide novel insights into
understanding how FGF signaling, with 22 ligands, 4 transmem-
brane receptors, and their splice variants, could fine-tune their
regulatory roles by differentially autoregulating FGF receptor
transcription. Such a mechanism could be broadly applicable to
the regulation of normal cellular processes, such as neural
development, as well as pathological processes, such as cancer.
Materials and Methods
Cell culture
All cell lines used in these studies were verified to be free of
mycoplasma contamination (MycoSensor QPCR, Stratagene/
Agilent Technologies). The following murine tumorigenic cell lines
were used: fibroblast-derived (3T3, American Tissue Type Culture
Collection), neuronal derived from hippocampus (HT-22, a
subclone of the HT4 cell line [28], generously provided by Dr.
Dave Schubert, Salk Institute, San Diego, CA), and neuroendo-
crine derived from hypothalamic gonadotropin-releasing hormone
neurons (GT1-7, generously provided by Dr. Pamela Mellon,
University of California, San Diego, CA). Cells were maintained in
50/50 F12/Dulbecco’s modified essential medium (DMEM)
containing 4.5% glucose and L-glutamine (Invitrogen Inc.,
Carlsbad, CA), supplemented with 1x non-essential amino acids
and 10% fetal bovine serum (Gemini Bioproducts, Woodland,
CA). Cells were grown to 70% confluency and used within 10
passages for all experiments.
Peptides
Recombinant mouse fibroblast growth factor-8b carrier-free
(FGF8b, R&D Systems, Minneapolis, MN) was reconstituted in
sterile phosphate buffered saline (PBS) and diluted further to final
concentrations. The FGF/VEGF receptor tyrosine kinase inhib-
itor PD173074 (Calbiochem, Gibbstown, NJ) was reconstituted in
100% dimethlysulfoxide (DMSO) and used at a final concentra-
tion of 100 nM in 0.01% DMSO. PD173074 is an ATP-
competitive reversible inhibitor of FGF and VEGF receptors
(IC50 =21.5 nM for FGFR1, Calbiochem) and has been
extensively characterized [29,30,31,32].
Reporter plasmid constructs
The full-length mouse (-3446 to +24) GnRH promoter was
subcloned into the promoterless firefly luciferase vector (pXP2) and
has been extensively characterized [33,34]. The renilla luciferase
pGL4 reporter construct (Invitrogen Inc., Carlsbad, CA) was used
as an internal control for calculating plasmid transfection efficiency.
Transient Transfections
GT1-7 cells were plated at a density of 0.2610
5 cells/well in 96-
well plates for 48 hours prior to transfection to achieve a final
confluency of 70–80%. All constructs were transfected in replicates
of six wells within each assay, and each transfection assay was
repeated a minimum of 3 times. Further, each experiment was
Figure 5. Effects of FGF8b on GnRH promoter activity. Transient transfection of GT1-7 cells with 0.15 mg/well of mouse full-length GnRH-
luciferase reporter construct. Following transfection, cells were treated with vehicle, FGF8b (50 ng/ml), PD173074 (100 nM), or FGF8b + PD173074 for
8 hours. Data are represented as mean percent change in RLU’s from vehicle-treated controls 6 SEM. Dissimilar letters indicate statistically significant
difference among groups, P,0.05.
doi:10.1371/journal.pone.0010143.g005
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plasmid reporter construct. Transfections were carried out using a
lipid-mediated transfection reagent according to manufacturer’s
instructions (Fugene6, Roche Molecular Biomedical, Indianapolis,
IN). Cells were incubated with transfection media complex
overnight followed by replacement with phenol red-free 50/50
F12/DMEM containing1.0%stripped fetal bovine serum (Hyclone
Laboratories, Logan, UT) to minimize the presence of exogenous
growth factors in the cell culture media. Notably, all experiments
were replicated using media containing 10%, 1%, and dextran-
charcoal stripped serum, and no differences were observed.
Therefore, all data reported herein are taken from experiments
where cells werekept inmedia containing1% FBS. Thirty-sixhours
after transfection, cells were incubated with media containing
0.01% PBS, 50 ng/ml FGF8b, or 100 nM PD173074 for eight
hours and then lysed for dual luciferase analysis. Luciferase activity
was measured using the Dual Luciferase Reporter Assay system
(Promega Corp., Madison, WI) according to manufacturer’s
instructions. Relative light units were measured using the Synergy
HT multimode plate reader (BioTek Instruments Corp., Winooski,
VT). Luciferase substrates (100 ml/well) were added to cells using
automatic injectors attached to the plate reader.
RNA isolation
3T3, HT-22, and GT1-7 cells were plated at a density of
2.0610
5 cells/well in a six-well plate. Cells were allowed to grow
in regular media containing 10% FBS for 24–48 hours until 70–
80% confluent. Twenty-four hours prior to treatment, cells were
washed once with PBS followed by the addition of phenol red-free
50/50 F12/DMEM containing 1% FBS (Hyclone Laboratories,
Logan, UT) to minimize the presence of exogenous growth factors
in the cell culture media. Notably, all experiments were replicated
using media containing 10%, 1%, and dextran-charcoal stripped
serum and no differences were observed. All data reported herein
are from cells kept in media containing 1% FBS. On the day of
treatment, cells were treated with vehicle, 5 or 50 ng/ml FGF8b,
100 nM PD173074, or a combination (FGF8b + PD173074) for 4
or 8 hours. All treatments were done in replicates of 6 wells. Cells
were washed once with cold PBS, lysed with Trizol reagent, and
total RNA isolated according to manufacturer’s instructions
(Invitrogen Inc., Carlsbad, CA). Following isolation, genomic
DNA contamination was removed using DNAfree reagents
(Stratagene, a division of Agilent Corp., La Jolla, CA) according
to manufacturer’s instructions. Quantification of total RNA was
performed using a Nanodrop spectrophotometer, and samples
with an OD 260:280 of 1.7 – 1.9 were used for subsequent reverse
transcription assays.
Reverse Transcription
Total RNA (1 mg from cell culture experiments for quantitative
real-time RT-PCR; 0.5 mg for FGF8 detection RT-PCR in
embryonic nasal explants at E11.5, adult hypothalamus, 3T3
cells, HT-22 cells, and GT1-7 cells) was combined with 0.5 mg
oligo d(T), heated to 65uC and rapidly cooled on ice. The RNA-
primer mix was combined with M-MLV buffer (50 mM Tris-HCl
pH 8.3, 75 mM KCl, 3 mM MgCl2), 10 mM DTT, 0.5 mM
dNTP and 0.5 mM M-MLV reverse transcriptase (Invitrogen Inc.,
Carlsbad, CA). Reverse transcriptase reaction was performed by
incubating for 10 minutes at room temp, 50 minutes at 42uC, then
95uC for 5 minutes to terminate the reaction.
RT-PCR
FGF8 Detection. 2 ml of cDNA template, prepared by reverse
transcription reaction as described above, was added to a master
mix containing 1x Go Taq flexi buffer (Promega Corp.), 1.5 mM
MgCl, 200 mM dNTP mix, 0.5 mM forward and reverse primer
(see primer sequences below), and 2 U Go Taq flexi DNA
polymerase (Promega Corp.,). RT-PCR was performed using the
Eppendorf Realplex thermocycler with the following reaction
conditions: 95uC for 10 min., 40 repeated cycles including
denature (95uC), annealing (62uC), and extension (72uC), final
extension for 5 min. at 72uC. PCR products were resolved on a
2% agarose gel and compared with a DNA ladder of known size
(Fisher Scientific, Exactgene) to verify product size.
Quantitative Polymerase Chain Reaction
qPCR was performed using FastStart DNA Master SYBR
Green I according to manufacturer’s instructions (Roche Molec-
ular Biomedical, Indianapolis, IN). Master mix containing
MgCL2, SYBR Green, and primer pairs (0.25 mM) were
aliquotted into 96-well plates followed by the addition of 1/20
th
of the reverse transcription reaction (cDNA). No template controls
received DNA-free water of the same volume. All cDNA samples
were tested in triplicate within an assay and each experiment was
repeated three times. Real-time PCR reactions were carried out
using the Eppendorf Realplex thermocycler with the following
conditions: 95uC for 10 min., 40 repeated cycles including
denature (95uC), annealing (60uC), and extension (72uC) with
fluorescence detection at the end of each 72uC step, and then
melted with continuous fluorescence detection to 95uC. PCR
products were resolved on a 2% agarose gel and compared with a
DNA ladder of known size (Fisher Scientific, Exactgene 50bp
ladder) to confirm product size, and to verify specificity, the
products were subjected to a thermal melting curve analysis to
determine if the Tm of the product was consistent with the
calculated theoretical Tm based on sequence. Primer sequences
are as follows: GnRH: forward - 59CTGCTGACTGTGTG-
TTTGGAAGG 39; reverse – 59CCTGGCTTCCTCTT-
CAATCA 39. FGFR1: forward – 59ATGGTTGACCGTTCTG-
GAAG 39; reverse – TGGCTATGGAAGTCGCTCTT 39;
FGFR3: forward – 59GAGACTTGGCTGCCAGAAAC 39;
reverse – 59GGAGGACACCAAAAGACCA 39. FGF8: forward
–5 9 GAGCAACGGCAAAGGCAAGG 39; reverse – 59 CTCA-
ACTACCCGCCCTTCAC 39. The FGF sequence targets exon 5
which is present in all FGF8 splice variants.
All samples were first normalized to the constitutively expressed
hypoxanthine phosphoribosyl transferase 1 (HPRT) housekeeping
gene followed by absolute quantification extrapolated from known
quantities in a standard curve. The Eppendorf Realplex software
plots a standard curve of the crossing line intercepts of the
standard vs. the known concentrations of these standards. The
crossing line intercept is parallel to the x-axis on a graph of
fluorescent intensity vs. cycle number and occurs at a point where
the template amplification enters the logarithmic phase of the
curve. Samples with higher concentrations of starting material
enter the logarithmic phase earlier than samples with a lower
concentration of starting material and consequently, have a
smaller crossing point value. The crossing line intercept of
unknowns is then compared with that of known values to calculate
the actual amount. Data are represented as mRNA copies/mg total
RNA.
Statistics
Data were analyzed by one-way ANOVA followed by Tukey’s
HSD test. Differences were considered significant when P,0.05.
All transfection data are represented as percent change compared
to vehicle-treated, empty vector controls.
FGF8 Autoregulation
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